Literature DB >> 29790225

Can cardiovascular MRI be used to more definitively characterize cardiac masses initially identified using echocardiography?

Vikas K Rathi1,2, Anna T Czajka1, Diane V Thompson1, Mark Doyle1, Tarun Tewatia1, June Yamrozik1, Ronald B Williams1, Robert W W Biederman1.   

Abstract

In diagnosing cardiac and paracardiac masses, cardiac MRI (CMR) has gained acceptance as the gold standard. CMR has been observed to be superior to echocardiography in characterizing soft-tissue structures and, specifically, in classifying cardiac masses. The aim of our study was to evaluate the association between mortality and cardiac or paracardiac masses initially identified by echocardiography (ECHO) and confirmed by CMR. Between January 2002 and August 2007, a total of 158 patients underwent both ECHO and CMR for the evaluation of cardiac masses that were equivocal or undefined by ECHO. The primary study endpoints were 5-year all-cause mortality and 5-year cardiac mortality. Causes of death as of April 1, 2015 were obtained from medical records or the National Death Index. Patients were analyzed according to mass type determined by CMR using the Kruskal-Wallis test, Kaplan-Meier curves, and the log-rank test. Over a mean duration of follow-up of 10.4 ± 2.9 years (range: 0.01-12 years) post-CMR, the overall all-cause mortality rate was 25.9% (41/158). Median age at death was 76 years and there were 21 females (51.2%). Mortality rates in the different classifications of cardiac masses by CMR were as follows: 20% (1/5) in patients with a Nondiagnostic CMR; 20% (1/5) in Other Diagnoses; 17.9% (7/39) in No Masses (includes Normal Anatomical Variants); 16.7% (3/18) in Benign Masses; 23.8% (15/63) in Fat; 50% (5/10) in Thrombus; and 61.5% (8/13) in Malignant Mass. The mean survival time in patients with No Mass (n = 39) was not significantly longer than patients with any type of cardiac mass (n = 114) (P = .16). No significant difference was found in age at death between patients when grouped by CMR classification (P = .40). However, among CMR-confirmed masses, there were some significant differences by mass classification type (P = .006). During the follow-up period, 26% (41/158) of patients died and 22% (9/41) of the deaths were cardiovascular related; there was no significant difference in mean survival times with respect to cause of mortality (P = .23). In patients with cardiac masses, dually confirmed by ECHO and CMR, significant differences in survival time were observed based upon CMR classified type of mass while CMR was instrumental in obviating invasive biopsy.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  cardiac magnetic resonance imaging; transesophageal echocardiography; transthoracic echocardiography

Mesh:

Year:  2018        PMID: 29790225     DOI: 10.1111/echo.14017

Source DB:  PubMed          Journal:  Echocardiography        ISSN: 0742-2822            Impact factor:   1.724


  3 in total

Review 1.  The Assessment of Cardiac Masses by Cardiac CT and CMR Including Pre-op 3D Reconstruction and Planning.

Authors:  Stephen Liddy; Colin McQuade; Kevin P Walsh; Bryan Loo; Orla Buckley
Journal:  Curr Cardiol Rep       Date:  2019-07-31       Impact factor: 2.931

Review 2.  Cardiovascular Imaging in Cardio-Oncology: The Role of Echocardiography and Cardiac MRI in Modern Cardio-Oncology.

Authors:  John Alan Gambril; Aaron Chum; Akash Goyal; Patrick Ruz; Katarzyna Mikrut; Orlando Simonetti; Hardeep Dholiya; Brijesh Patel; Daniel Addison
Journal:  Heart Fail Clin       Date:  2022-07       Impact factor: 2.828

3.  Contribution and performance of multimodal imaging in the diagnosis and management of cardiac masses.

Authors:  Maëva Lemasle; Yoan Lavie Badie; Eve Cariou; Pauline Fournier; Jean Porterie; Hervé Rousseau; Antoine Petermann; Anne Hitzel; Didier Carrié; Michel Galinier; Bertrand Marcheix; Olivier Lairez
Journal:  Int J Cardiovasc Imaging       Date:  2020-02-10       Impact factor: 2.357

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.